ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
623 |
198K |
11 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
623
|
198K
|
11
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
21K |
7.3M |
3 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
21K
|
7.3M
|
3
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
1 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
2 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
213
|
89K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
34K |
27 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
110
|
34K
|
27
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
40 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Notification regarding unquoted securities - RAC
|
|
ma420
|
10 |
4.5K |
3 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
10
|
4.5K
|
3
|
|
ASX - By Stock
|
COV |
Re:
Cleo - General discussion
|
|
ma420
|
2 |
917 |
1 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
2
|
917
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Notification regarding unquoted securities - RAC
|
|
ma420
|
10 |
4.5K |
2 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
10
|
4.5K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
24 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
213
|
89K
|
24
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
174 |
81K |
16 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
174
|
81K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
206 |
52K |
3 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
206
|
52K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
206 |
52K |
8 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
206
|
52K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
DXB options
|
|
ma420
|
43 |
21K |
0 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
43
|
21K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
DXB options
|
|
ma420
|
43 |
21K |
1 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
43
|
21K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
531 |
178K |
10 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
531
|
178K
|
10
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
15 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
213
|
89K
|
15
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity Confirms No Supply Disruptions for Clinical Trials
|
|
ma420
|
11 |
4.4K |
16 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
11
|
4.4K
|
16
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
174 |
81K |
28 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
174
|
81K
|
28
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
19 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
213
|
89K
|
19
|
|
ASX - By Stock
|
NTI |
NTI - Media & News
|
|
ma420
|
0 |
274 |
1 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
0
|
274
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
ma420
|
41 |
13K |
26 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
41
|
13K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Offer Results
|
|
ma420
|
35 |
11K |
5 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
35
|
11K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
1 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
0 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Offer Results
|
|
ma420
|
35 |
11K |
66 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
35
|
11K
|
66
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
19 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
213
|
89K
|
19
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
213 |
89K |
11 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
213
|
89K
|
11
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
21K |
7.3M |
4 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
21K
|
7.3M
|
4
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
14 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
206 |
52K |
2 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
206
|
52K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
206 |
52K |
4 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
206
|
52K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
ma420
|
61 |
12K |
0 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
206 |
52K |
3 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
52K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
741K |
13 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
2.2K
|
741K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
ma420
|
41 |
13K |
21 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
41
|
13K
|
21
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
3 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
55
|
17K
|
3
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
55 |
17K |
1 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
55
|
17K
|
1
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
3.8M |
37 |
05/06/24 |
05/06/24 |
General
|
11K
|
3.8M
|
37
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
ma420
|
61 |
12K |
6 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
6
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
3.8M |
60 |
05/06/24 |
05/06/24 |
General
|
11K
|
3.8M
|
60
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
ma420
|
61 |
12K |
7 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
ma420
|
61 |
12K |
6 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
ma420
|
61 |
12K |
4 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
ma420
|
61 |
12K |
19 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
206 |
52K |
5 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
52K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
206 |
52K |
5 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
206
|
52K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
ma420
|
61 |
12K |
11 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
12K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
13 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
230
|
103K
|
13
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
ma420
|
230 |
103K |
18 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
230
|
103K
|
18
|
|